Keyword Analysis & Research: mirapex for depression
Keyword Research: People who searched mirapex for depression also searched
Search Results related to mirapex for depression on Search Engine
-
Clinical Experience With High-Dosage Pramipexole in Patients …
https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2015.15060788
WebFeb 1, 2016 · Dopamine agonists, such as pramipexole—a relatively selective dopamine D 3 receptor agonist—are thus potential treatments for depression, especially anhedonic depression. D 3 receptors are found in the mesolimbic system, which in turn has been implicated in the motoric and hedonic deficits in depression ( 9 , 10 ).
DA: 84 PA: 68 MOZ Rank: 22
-
Pramipexole in the treatment of unipolar and bipolar depression.
https://pubmed.ncbi.nlm.nih.gov/31111467/
WebPMID: 31111467. DOI: 10.1111/acps.13055. Abstract. Objective: Several depressed patients do not respond to traditional antidepressants. Our aim was to systematically review the effectiveness and safety of pramipexole in unipolar and bipolar depression.
DA: 38 PA: 37 MOZ Rank: 18
-
Pramipexole in Depression - Mechanism of Action and Dosing
https://psychscenehub.com/psychinsights/pramipexole-treatment-resistant-depression/
WebFeb 17, 2020 · Pramipexole and potentially other dopamine agonists may be useful in the treatment of refractory depression. Pramipexole currently does not have FDA or TGA approval in the US or Australia for the treatment of depression.
DA: 100 PA: 96 MOZ Rank: 48
-
Efficacy and safety of 24-week pramipexole augmentation in …
https://www.sciencedirect.com/science/article/abs/pii/S0278584621001846
WebJan 10, 2022 · Pramipexole is a dopamine agonist with potential antidepressant, neuroprotective, antioxidant and anti-inflammatory activity. In the present study we investigated the 24 weeks effect and safety of traditional AD augmentation with pramipexole for treatment-resistant depression.
DA: 14 PA: 47 MOZ Rank: 78
-
The role of pramipexole in the treatment of patients with depression
https://www.sciencedirect.com/science/article/pii/S1876201821001477
WebJul 1, 2021 · Pramipexole therapy can obviously relieve patients' depression and motor symptom. •. There were no more side effects associated with pramipexole intervention. Abstract. Objective.
DA: 29 PA: 24 MOZ Rank: 19
-
Experimental Therapies for Treatment-Resistant Depression: …
https://ncbi.nlm.nih.gov/pmc/articles/PMC6103647/
WebJul 16, 2018 · Pramipexole, a dopamine receptor D2 and D3 agonist, has been shown to be effective in reducing depression and to result in long-term improvement for patients with TRD (25, 26). Because higher doses might be needed to attain therapeutic response with pramipexole, Fawcett et al. recommended that clinicians start at low dosage, slow …
DA: 24 PA: 53 MOZ Rank: 29
-
Pramipexole for the Treatment of Depression: Efficacy and …
https://link.springer.com/chapter/10.1007/7854_2023_458
WebNov 21, 2023 · Pramipexole’s therapeutic utility in depression is likely to be expressed through alterations in reward mechanisms which are strongly influenced by dopamine pathways and are known to function abnormally in depressed patients.
DA: 24 PA: 1 MOZ Rank: 10
-
Pramipexole for Depression | American Journal of Psychiatry
https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.159.2.320-a
WebFeb 1, 2002 · Initial reports suggested the use of pramipexole as an augmentation for current treatment with antidepressants—later and more hesitantly it was suggested as primary therapy. I am aware of no systematic large-scale studies of pramipexole as a treatment for depression.
DA: 90 PA: 61 MOZ Rank: 90
-
Pramipexole in treatment‐resistant depression: An extended …
https://onlinelibrary.wiley.com/doi/10.1002/da.20038
WebNov 17, 2004 · Citations: 75. PDF. Tools. Share. Abstract. We evaluated the long-term antidepressant safety and response of adjunctive pramipexole, a D2–D3 dopamine agonist, in the course of drug-resistant depression. Twenty-three patients with treatment-resistant major depressive episode (MDE) were followed up after a 16-week pramipexole …
DA: 93 PA: 100 MOZ Rank: 81
-
Pramipexole in treatment-resistant depression: an extended
https://pubmed.ncbi.nlm.nih.gov/15549689/
WebPMID: 15549689. DOI: 10.1002/da.20038. Abstract. We evaluated the long-term antidepressant safety and response of adjunctive pramipexole, a D2-D3 dopamine agonist, in the course of drug-resistant depression. Twenty-three patients with treatment-resistant major depressive episode (MDE) were followed up after a 16-week …
DA: 59 PA: 11 MOZ Rank: 23